<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>[Cell Adhesion &amp; Migration 1:2, 56-61; April/May/June 2007]; &#194;&#169;2007 Landes Bioscience <br />  <br />  <br />  <br /> Review <br />  <br /> Neuropilins <br /> Novel Targets Anti-Angiogenesis Therapies <br />  <br />  <br /> Elena Geretti1                                                                  <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br /> Michael Klagsbrun1,2,*                                                             It well-established neuropilins (NRP1 NRP2), described &#194;&#173;mediators <br />                                                                                 neuronal guidance, mediators angiogenesis tumor &#194;&#173;progression. NRPs <br /> 1Department  Surgery;   2Departmentof Pathology; Vascular Biology Program; <br />                                                                                 receptors class&#226;&#8364;&#8216;3 semaphorin (SEMA) family axon guidance molecules <br /> Children&#226;&#8364;&#8482;s Hospital Harvard Medical School; Boston, Massachusetts USA <br />                                                                                 vascular endothelial growth factor (VEGF) family angiogenic factors. <br /> *Correspondence <span id='am-4' about='protege:TO' typeof='owl:Thing'>to</span>: Michael Klagsbrun; Vascular Biology Program; Children&#226;&#8364;&#8482;s     VEGF&#226;&#8364;&#8216;NRP interactions promote developmental angiogenesis shown mouse <br /> Hospital, Boston; Karp Building 12210; 300 Longwood Avenue; Boston, <br />                                                                                 <span id='am-161' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-162' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-163' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-165' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-168' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-171' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-176' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-180' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-185' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-192' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-198' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-206' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-210' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-224' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-229' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-232' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-234' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-237' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-238' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span>knockout</span> zebrafish knockdown studies. There evidence NRPs mediate <br /> Massachusetts 02115 USA; Tel.: 617.919.2157; Fax: 617.730.0233; Email: <br /> michael.klagsbrun@childrens.harvard.edu                                         tumor progression. For example, overexpression NRP1 enhances tumor growth <br />                                                                                 NRP1 antagonists, soluble NRP1 anti&#226;&#8364;&#8216;NRP1 antibodies, inhibit <br /> Original manuscript submitted: 05/07/07 <br />                                                                                 tumor growth. Furthermore, class&#226;&#8364;&#8216;3 SEMAs acting NRPs inhibit tumor angiogen- <br /> Manuscript accepted: 05/25/07 <br />                                                                                 esis, progression metastasis. Clinical data suggest high NRP levels correlate with <br /> Previously published online Cell Adhesion &amp; Migration E-publication:       poor prognosis <span id='am-5' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-6' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-10' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-54' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-62' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-68' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-70' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-82' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span>survival</span> variety cancer types. Taken together, results <br /> http://www.landesbioscience.com/journals/celladhesion/article/4490 <br />                                                                                 suggest NRPs potentially valuable targets new anti&#226;&#8364;&#8216;cancer &#194;&#173; therapies. We <br />                                                                                 analyze current knowledge NRPs role &#194;&#173;angiogenesis tumor <br /> Keywords                                                                        progression enumerate strategies targeting receptors. <br /> neuropilin, semaphorin, VEGF, angiogenesis, <br /> axon guidance, cancer, metastasis <br />                                                                                 Neuropilin Background <br /> Abbreviations <br />                                                                                        Anti&#226;&#8364;&#8216;VEGF antibodies received attention lately ability block <br /> NRP	                 neuropilin <br />                                                                                 tumor angiogenesis prolong life cancer patients.1 In 2004, Bevacizumab <br /> SEMA	                semaphorin <br />                                                                                 (Avastin), humanized monoclonal antibody VEGF&#226;&#8364;&#8216;A, first <br /> VEGF	                vascular endothelial growth factor <br />                                                                                 &#194;&#173;antiangiogenic drug approved FDA line treatment metastatic colorectal <br /> VEGFR	               VEGF receptor <br />                                                                                  cancer &#194;&#173;combination chemotherapy. Another anti&#226;&#8364;&#8216;VEGF antibody, Ranibizumab <br /> EC	                  endothelial cell <br />                                                                                  (Lucentis), monoclonal antibody Fab, successful treatment of <br /> PAE cells	           porcine aortic endothelial cells <br />                                                                                  &#194;&#173;neovascularization associated wet neovascular age&#226;&#8364;&#8216;related macular degeneration <br /> ISV	                 intersegmental vessels <br />                                                                                   (AMD), &#194;&#173; alleviating blindness patients.2 However, cancer patients the <br /> DRG	                 dorsal root ganglia <br />                                                                                   anti&#226;&#8364;&#8216;VEGF&#226;&#8364;&#8216;chemotherapy combination adverse effects including hypertension, <br />                                                                                   impaired wound healing arterial thrombotic events.3 Thus, promising &#194;&#173;development <br /> Acknowledgments <br />                                                                                   surfaced recently article Pan et al.4 reported antibodies to <br /> We thank Drs. Dhara Amin, Silvia Coma                                             &#194;&#173;neuropilin&#226;&#8364;&#8216;1 (NRP1) combination anti&#226;&#8364;&#8216;VEGF enhanced ability anti&#226;&#8364;&#8216;VEGF <br /> and Kashi Javaherian critical &#194;&#173;evaluation                                   block tumor growth. <br /> the manuscript. We thank Melissa Herman                                                There NRPs, NRP1 NRP2. These NRPs single pass &#194;&#173;transmembrane <br /> for proofreading manuscript Kristin                                        glycoproteins. NRPs discovered expressed neurons.5 Subsequently, <br /> Johnson technical assistance figure                                         NRP1 identified receptor semaphorin 3A (SEMA3A), mediator axon <br /> &#194;&#173;preparation. This work supported                                           guidance repels axons collapses growth cones.6 Surprisingly, NRPs found <br />  National Institute Health NCI grants                                           soon receptors VEGF family angiogenesis factors, suggesting that <br />  CA37392 CA45548 (to Michael                                                   receptor involved blood vessel formation.7 Structurally, NRPs large <br />  Klagsbrun).                                                                       extracellular domain (~840 amino acid residues) containing A, B C &#194;&#173;subdomains, <br />                                                                                    short transmembrane domain (~25 residues) ~40 residue long &#194;&#173; cytoplasmic <br />                                                                                    sequence (Fig. 1). VEGF165 binds B domain, class&#226;&#8364;&#8216;3 SEMAs bind both <br />                                                                                    A B domains.8&#226;&#8364;&#8216;10 VEGF modular protein consisting exons, whose <br />                                                                                    differential splicing gives rise different isoforms. Importantly, exon 4 binds high <br />                                                                                    affinity VEGFR&#226;&#8364;&#8216;2 tyrosine kinase receptor, exons 7 8 bind NRPs <br />                                                                                    (Fig.&#194;&#160;2A). Thus, VEGF165 bind simultaneously receptors, VEGFR&#226;&#8364;&#8216;2 and <br />                                                                                    NRP. VEGF165 stimulates enhanced chemotaxis EC express VEGFR&#226;&#8364;&#8216;2 NRP1 <br />                                                                                    compared EC expressing VEGFR&#226;&#8364;&#8216;2 alone.7 Since NRPs signaling motifs, <br />                                                                                    suggested NRP1 coreceptor VEGFR&#226;&#8364;&#8216;2. <br />  <br />  <br />  <br /> 56	                                                                                   Cell Adhesion &amp; Migration	                                          2007; Vol. 1 Issue 2 <br />                                                                    Neuropilins Angiogenesis <br />  <br />  <br />                                                                                  embryonic&#226;&#8364;&#8216;lethal displayed vascular defects including excess <br />                                                                                  numbers blood vessels, dilated blood vessels, hemorrhage, and <br />                                                                                  malformed hearts limbs.19 Nrp&#226;&#8364;&#8216;1&#226;&#8364;&#8216;deficient mice died utero at <br />                                                                                  E12.5 E13.5 exhibited vascular defects including abnormal <br />                                                                                  yolk sacs, abnormal neuronal vascularization, disorganized blood <br />                                                                                  vessels, lack normal branching, missing capillary networks, <br />                                                                                  cardiovascular defects including agenesis bronchial arches, <br />                                                                                  defects dorsal aorta, &#194;&#173; transposition aortic arches.20 <br />                                                                                   Nrp2&#226;&#8364;&#8216;deficient mice viable,21 developed arteries veins <br /> Figure 1. Schematic representation NRP domain structure. The sites        normally displayed severe &#194;&#173;reduction small lymphatic vessels <br /> of interaction respective extracellular ligands, VEGF165 class&#226;&#8364;&#8216;3    &#194;&#173; capillaries.16 Double Nrp1/Nrp2 knockout mice died E8.5 <br /> SEMAs, intracellular binding partner, Neuropilin Interacting      severe vascular &#194;&#173; <span id='am-83' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-84' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-91' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-110' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-112' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-120' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-138' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-145' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-147' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-149' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-160' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span>phenotype</span> Nrp1&#226;&#8364;&#8216;deficient mice <br /> Protein (NIP), shown.                                                        including avascular yolk sacs, growth &#194;&#173; retardation lack vessel <br />                                                                                  development, &#194;&#173;capillary &#194;&#173;formation, branching.22 <br />     Why anti&#226;&#8364;&#8216;VEGF combined anti&#226;&#8364;&#8216;NRP1 effective                           In zebrafish, knockdown NRP1 antisense morpholinos <br /> as tumor growth &#194;&#173; inhibitor anti&#226;&#8364;&#8216;VEGF alone? Presumably,                  (MO) resulted vascular defects.23 These defects included loss <br /> VEGF165 exon 4 interactions VEGFR&#226;&#8364;&#8216;2 VEGF165 exons                       circulation intersegmental vessels (ISV), dorsal <br /> 7/8 interactions NRPs constitute different signaling pathways               &#194;&#173;longitudinal anastomotic vessels (DLAV), caudal vein <br /> and different targets. There evidence NRP signaling             plexus. The ISV correspond angiogenic sprouts. Furthermore, <br /> can independent VEGFR&#226;&#8364;&#8216;2, binding NRP interacting                      abnormal direct connections artery vein resembling <br /> protein (NIP), PDZ domain&#226;&#8364;&#8216;containing protein.11 NIP identical                fistulas resulted aberrant return blood circulation the <br /> to RGS&#226;&#8364;&#8216;GAIP&#226;&#8364;&#8216; interacting protein (GIPC), suggested                 heart. Of interest, MO treatment 1&#226;&#8364;&#8220;4 cell stage did inhibit <br /> to involved vesicular trafficking.12 GIPC interacts                axial vessel formation. Thus, zebrafish, NRP1 regulator of <br /> NRP1 C&#226;&#8364;&#8216;terminal residues, SEA&#226;&#8364;&#8216;COOH. In zebrafish, GIPC knock-                     angiogenesis vasculogenesis. <br /> down morpholinos resulted vascular defect resembling <br /> NRP1 knockdown.11 Another NIP Synectin, required                 Neuropilins Semaphorins <br /> arterial branching independent VEGF/VEGFR&#226;&#8364;&#8216;2.13,14 <br />     In study Pan et al. properties anti&#226;&#8364;&#8216;NRP                         The set ligands NRPs class&#226;&#8364;&#8216;3 family of <br /> &#194;&#173;antibodies investigated, anti&#226;&#8364;&#8216;NRP1A anti&#226;&#8364;&#8216;NRP1B, directed               s&#194;&#173; emaphorins (SEMA), seven members (A&#226;&#8364;&#8220;G). <br />  NRP1 A B domains, respectively. Both anti&#226;&#8364;&#8216;NRP1                    SEMAs described negative mediators axon &#194;&#173;pathfinding <br />  antibodies inhibited VEGF165&#226;&#8364;&#8216;induced EC migration, EC sprouting                  repel axons collapse growth cones.6,24 Surprisingly, turned <br />  neovascularization corneal pocket assay did                   semaphorins angiogenesis inhibitors well. The <br />  inhibit VEGF165&#226;&#8364;&#8216;induced VEGFR&#226;&#8364;&#8216;2 phosphorylation downstream                    SEMA&#226;&#8364;&#8216;NRP complex does transmit signals. Instead, NRPs <br />  signaling, EC proliferation, vascular permeability. Anti&#226;&#8364;&#8216;NRP1B                form complexes plexins, &#194;&#173;transmembrane proteins that <br />  effective, consistent B domain VEGF165               act substrates kinases, transduce SEMA signal.25,26 <br />  binding domain. Tumor blood vessels mice treated                    SEMA3A inhibits EC adhesion, &#194;&#173; migration sprouting.27,28 <br />                                                                                   Semaphorins inhibit tumor growth, tumor angiogenesis and <br />  anti&#226;&#8364;&#8216;VEGF anti&#226;&#8364;&#8216;NRP1 demonstrated low pericyte association <br />                                                                                   metastasis. Overexpression SEMA3F &#194;&#173; melanoma cells vivo <br />  tumor EC. Since pericytes stabilize tumor vessels, lack of <br />                                                                                   inhibited tumor angiogenesis metastasis.29 Interestingly, it <br />  pericytes suggests tumor blood vessels fragile and <br />                                                                                   appeared SEMA3F acted repelling EC preventing <br />  susceptible anti&#226;&#8364;&#8216;angiogenesis therapy. Anti&#226;&#8364;&#8216;NRP &#194;&#173; inhibited              invasion tumor blood vessels. This mechanism mimics <br />  vascular remodeling mouse&#226;&#8364;&#8216;developing retina. Thus, anti&#226;&#8364;&#8216;NRP1              well&#226;&#8364;&#8216;characterized SEMA repulsion axons. SEMA3B also <br />  antibodies prevent tumor vessel maturation and, way,               appears inhibitor tumor progression. Adenocarcinoma <br />  vessels dependent VEGF and, thus, &#194;&#173; susceptible                  cells &#194;&#173;transfected SEMA3B tumorigenic compared to <br />  anti&#226;&#8364;&#8216;VEGF treatment.                                                             controls.30 Another mechanism involves p53, tumor suppressor. <br />                                                                                   p53 increases levels SEMA3F,31 turn &#194;&#173;considered <br /> Neuropilins Angiogenesis                                                      tumor suppressor.32 p53 knockdowns enhanced tumor <br />                                                                                   angiogenesis concomitant lower SEMA3F NRP2 gene <br />     What evidence NRPs mediate angiogenesis,                     expression.31 It noted SEMA3E exception to <br /> normal pathological? NRPs expressed vascular                       rule. In contrast class&#226;&#8364;&#8216;3 SEMAs, SEMA3E directly <br /> system degree vessel type specificity, mouse,                 binds Plexin&#226;&#8364;&#8216;D1; SEMA3E&#226;&#8364;&#8216;plexin D1 &#194;&#173; interactions required <br /> chick, zebrafish embryo. NRP1 expressed arterial EC                     patterning intersomitic blood vessels (ISV) a <br /> whereas NRP2 expressed vein lymphatic EC.15&#226;&#8364;&#8216;18 Mouse                    NRP&#226;&#8364;&#8216;independent way.33 In contrast SEMAs activity <br /> knockout studies invaluable determining role                  suppressed furin&#226;&#8364;&#8216;dependent proteolysis,34 SEMA3E becomes <br /> NRPs blood vessel development. A number animal models                       activated cleavage turn promotes lung &#194;&#173;metastasis.35 <br /> have used &#194;&#173; delineate NRP function angiogenesis. The                       Importantly, SEMA3A VEGF165 competitive inhibitors. <br /> first indication NRP1 involved angiogenesis                   VEGF&#194;&#173;165&#194;&#173; inhibits SEMA3A&#226;&#8364;&#8216;induced dorsal root ganglia (DRG) <br /> demonstration overexpression Nrp1 transgenic mice                  collapse, SEMA3A inhibits VEGF165&#226;&#8364;&#8216;induced EC motility.28 <br />  <br />  <br /> www.landesbioscience.com	                                      Cell Adhesion &amp; Migration	                                                            57 <br />                                                                   Neuropilins Angiogenesis <br />  <br />  <br />                                                                                                             survival (Table 1). In glioma, an <br />                                                                                                             increased NRP1 expression without <br />                                                                                                             concomitant increase VEGF&#226;&#8364;&#8216;A VEGF <br />                                                                                                             receptors reported.42 These patients <br />                                                                                                             poorer prognosis without <br />                                                                                                             NRP1 &#194;&#173;overexpression. Patients newly <br />                                                                                                             &#194;&#173;diagnosed untreated acute myeloid leukemia <br />                                                                                                              (AML) &#194;&#173; demonstrated significant increase <br />                                                                                                              NRP1 &#194;&#173; expression significantly <br />                                                                                                              poorer 5&#226;&#8364;&#8216;year overall survival compared <br />                                                                                                              controls.43 Patients advanced <br />                                                                                                              colorectal &#194;&#173; carcinoma high levels of <br />                                                                                                              NRP1 staining showed significantly higher <br />                                                                                                              incidences lymph node liver metas- <br />                                                                                                              tasis shorter survival patients <br />  Figure 2. (A) Schematic view VEGF exon organization. Amino acid residues encoded exons <br />                                                                                                              low levels NRP.44 In gastrointes- <br />  3 4, respectively, responsible interaction VEGFR&#226;&#8364;&#8216;1 VEGFR&#226;&#8364;&#8216;2, respectively. Exons <br />  6 7 represent VEGF heparan sulphate proteoglycan (HSPG) binding domains. Exons 7 8             tinal cancers NRP1 &#194;&#173; expression correlated <br />  involved NRP binding. The asterisks represent major targets therapeutics, (VEGFR&#226;&#8364;&#8216;2       increased invasive growth.45 NRP2 <br />  NRP). (B) Strategies inhibit VEGF165 signaling VEGFR&#226;&#8364;&#8216;2. These include VEGFR&#226;&#8364;&#8216;2 kinase expression &#194;&#173; correlate tumor <br />  inhibitors (e.g., PTK787), soluble VEGFRs (e.g., VEGF&#226;&#8364;&#8216;trap), antibodies VEGFR&#226;&#8364;&#8216;2 (e.g., DC101)      progression. For example, &#194;&#173; osteosarcomas <br />  antibodies VEGF (Bevacizumab, Ranibizumab). (C) Strategies target VEGF165 interaction <br />                                                                                                             NRP2 expression showed &#194;&#173;significantly <br />  neuropilins. These include: anti&#226;&#8364;&#8216;NRP1 antibodies, soluble NRP isoforms semaphorins (e.g.,                                                    46 <br />  SEMA3A, SEMA3B, SEMA3F). In addition, number peptide&#226;&#8364;&#8216;mimetics VEGF165 exons increased vascularity poorer &#194;&#173;prognosis. <br />  7/8 block interaction NRPs VEGF165 (137&#226;&#8364;&#8216;160), A7R, EG3287, Tuftsin              Expression NRP1 NRP2 was <br />  analog TKPPR (see Table 2).                                                                                significantly higher ovarian carcinomas <br />                                                                                                             benign tumors. Interestingly, SEMA <br /> The structural basis competitiveness SEMAs strongly expressed benign tumors expressed in <br /> and VEGF165 bind NRP1/NRP2 B domain suggesting late stage &#194;&#173;carcinomas.36 Patients high VEGF SEMA ratio <br /> that binding sites common. Thus, ratio showed poorer survival low VEGF/SEMA ratios. <br /> VEGF165 SEMA tip balance promoting The expression NRP1 NRP2 &#194;&#173;nonsmall cell lung &#194;&#173;carcinomas <br /> blocking angiogenesis. An evidence possibility high (NSCLC) higher compared expression extraneoplastic <br /> VEGF165/SEMA ratio correlated poor prognosis tissue.47 Moreover, patients coexpression NRPs <br /> ovarian carcinoma patients.36                                                   showed poorer prognosis increased vessel counts compared to <br />                                                                                 &#194;&#173;individuals &#194;&#173; coexpression. In &#194;&#173; nonsmall cell lung &#194;&#173; carcinoma, <br /> Neuropilins Tumors                                                           levels NRP1 NRP2 increased different stages of <br />                                                                                  lung cancer, progressing dysplasia microinvasive carcinoma.48 <br />     NRP1&#226;&#8364;&#8216;driven angiogenesis contributes tumor growth VEGF elevated SEMA3F levels remained low, again <br /> mice. For example, inducible overexpression NRP1 &#194;&#173; prostate showing inverse relationship VEGF SEMA expression <br /> &#194;&#173;carcinoma cells vivo resulted larger highly vascular tumors.37 cancer. Although studies appear strong evidence for <br />  Tumor sections high levels VEGF165 protein, suggesting NRP expression elevated tumors, contrary report <br />  VEGF165 retained tumor binding NRP1. &#194;&#173;indicating expression NRP1 contributes better prognosis <br />  Similarly, human colon adenocarcinoma cells overexpressing NRP1 colon cancer.49 Gene expression levels NRP1 tumor were <br />  led larger angiogenic tumors compared controls.38 decreased compared extra&#226;&#8364;&#8216;neoplastic tissue levels. On other <br />  Overexpression NRP1 U87MG human &#194;&#173; glioblastoma, hand, NRP2 expression diminished tumors. <br />  expresses relative low levels receptor, resulted accelerated <br />  tumor growth angiogenesis compared control tumors.39 On <br />  different note, overexpression NRP1 pancreatic cancer cells <br />                                                                                  Neuropilin Antagonists <br />  renders cells susceptible detachment&#226;&#8364;&#8216;induced apoptosis               Antagonists VEGF&#226;&#8364;&#8216;VEGF receptor interactions shown <br />  (anoikis) resistant chemotherapy (gemcitabine promise inhibitors tumor angiogenesis. These antagonists <br />  5&#226;&#8364;&#8216;fluorouracil).40 However, opposite results pancreatic cancer include anti&#226;&#8364;&#8216;VEGF antibodies (Bevacizumab Ranimizumab, <br />  obtained Gray et al.41 In study, overexpression NRP1 led Genentech),50 anti&#226;&#8364;&#8216;VEGFR&#226;&#8364;&#8216;2 antibody (DC101),51 VEGR kinase <br />  decreased tumorigenity pancreatic cancer line and, contrast, inhibitors (e.g., PTK787)52 soluble VEGFRs, VEGF&#226;&#8364;&#8216;trap, <br />  NRP1 silencing significantly increased tumorigenity.                            soluble receptor consisting second Ig domain VEGFR&#226;&#8364;&#8216;1 <br />                                                                                  fused Ig domain VEGFR&#226;&#8364;&#8216;2 (Fig. 2B).53 <br />  Neuropilin Expression Cancer Patients                                           The efficacy anti&#226;&#8364;&#8216;NRP1 antibody inhibitor tumor growth <br />                                                                                  preclinical tumor model4 suggests &#194;&#173; worthwhile <br />     Clinical samples derived cancer patients demonstrated develop strategies inhibiting NRP activity. A number <br />  different varieties tumors, NRP expression elevated NRP antagonists reported. These &#194;&#173; antagonists include <br />  enhancement correlated poor prognosis anti&#226;&#8364;&#8216;NRP1 antibodies (described above), &#194;&#173; semaphorins (described <br />  <br />  <br /> 58	                                                          Cell Adhesion &amp; Migration	                                           2007; Vol. 1 Issue 2 <br />                                                                                            Neuropilins Angiogenesis <br />  <br />  <br /> Table 1	         Correlation neuropilin expression tumor progression <br />  <br /> Tumor Type	NRP1	NRP2	Status	Reference <br /> Glioma	                                                      h	            n.a.1	          Poorer prognosis	                                                                                            42 <br /> Acute myeloid leukemia	                                      h	            n.a.	           Poorer survival	                                                                                             43 <br /> Colon cancer	                                                h	            n.a.	           Poorer survival, higher lymph node liver metastasis	                                                     44 <br /> Gastrointestinal cancer	                                     h	            n.a.	           Higher invasiveness	                                                                                         45 <br /> Osteosarcoma	                                               n.a.	            h	            Increased vascularity, poorer prognosis	                                                                     46 <br /> Ovarian carcinoma	                                           h	              h	            Poorer prognosis; high VEGF/SEMA ratio prognostic poor survival	                                      36 <br /> Nonsmall cell lung carcinoma (NSCLC)	                        h	              h	            Poorer prognosis; increased vascularity	                                                                     47 <br /> Nonsmall cell lung carcinoma (NSCLC)	                        h	              h	            NRP1, NRP2, VEGF165 increase tumor stage; loss 	                                                    48 <br /> 			                                                                                        SEMA3F premalignant lesions	 <br /> Colon cancer	                                                i	            n.c.2	          Poorer prognosis	                                                                                            49 <br />  <br /> n.a.1: analyzed; n.c.2: change. <br />  <br />  <br /> Table 2	         Anti&#226;&#8364;&#8216;neuropilin strategies <br />  <br /> Factor	                                   Mechanism	Reference <br /> Semaphorins	                              Competition VEGF165 binding NRPs; Repulsion EC (SEMA3F)	                                                                                         28; 29 <br /> Anti&#226;&#8364;&#8216;NRP antibody	                        Inhibition VEGF165 binding full&#226;&#8364;&#8216;<span id='am-3' about='xsp:length' typeof='owl:Thing'>length</span> NRP; Additive effect anti&#226;&#8364;&#8216;VEGF tumor growth inhibition	                                                   4 <br /> Soluble NRP	&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189;&#239;&#191;&#189; <br />                      Inhibition VEGF165 signaling; antitumor activity	                                                                                                                            55; 56 <br /> NRP B domain	                             Inhibition VEGF165 binding full&#226;&#8364;&#8216;length NRP	                                                                                                              8 <br /> VEGF165 (137&#226;&#8364;&#8216;160)1	                       Inhibition VEGF&#226;&#8364;&#8216;induced EC proliferation	                                                                                                                  58 <br /> ATWLLPR (A7R)2	                           Inhibition VEGF165 binding NRP; Antiangiogenic antitumor activity	                                                                                  61 <br /> EG32873	                                  Inhibition VEGFR&#226;&#8364;&#8216;2 phosphorylation downstream signaling	                                                                                               59 <br /> TKPPR4	                                   Inhibition VEGFR&#226;&#8364;&#8216;2 activation	                                                                                                                             60 <br /> 1VEGF    fragment consisting exon 7 (amino acids 22&#226;&#8364;&#8220;44) amino acid exon 8, cysteine residue; 2Peptide identified screening mutated phage library anti&#226;&#8364;&#8216;VEGF antibody blocks <br />      165 <br /> VEGF165&#226;&#8364;&#8216;dependent EC proliferation; 3Byciclic peptide consisting exon 7 (amino acids 23&#226;&#8364;&#8220;4) exon 8; 4Tuftsin&#226;&#8364;&#8216;like peptide (TKPR). Homologous VEGF165 exon 8. <br />  <br />  <br /> above), soluble NRP1 (sNRP1), peptides derived VEGF165                                             desirable inhibit VEGF activity semaphorins, are <br /> and NRPs block VEGF&#194;&#173;165&#226;&#8364;&#8216;NRP &#194;&#173;interactions (Fig. 2C                                            &#194;&#173;angiogenesis &#194;&#173;inhibitors. <br /> Table 2).                                                                                                       Strategies developed target VEGF&#226;&#8364;&#8216;NRP1 &#194;&#173;interaction <br />      Naturally occurring sNRPs originate alternative splicing                                        based interfering VEGF exons 7 8 binding NRP1. <br /> the NRP gene introns yielding spliced isoforms.54,55                                          For example, peptide corresponding VEGF exon 7 (44 amino <br /> At protein level sNRPs consist extracellular NRP domains,                                         acids) 8 (6 amino acids) inhibited VEGF165 binding NRP1 <br /> in particular A B subdomains.54&#226;&#8364;&#8216;56 Overexpression sNRP1                                           VEGF165&#226;&#8364;&#8216;induced EC proliferation.58 The active region was <br /> in prostate cancer cells resulted tumors severely &#194;&#173;apoptotic                                    second half exons 7, amino acids 22&#226;&#8364;&#8220;44 <br /> and contained mainly damaged hemorrhagic tumor vessels,                                                  plus amino acid exon 8, cysteine residue. A bicyclic <br /> ostensibly inhibiting VEGF function.55 Thus, sNRP1                                                 peptide, EG3287, based NRP1 binding site located VEGF <br /> acting VEGF trap. Similarly, sNRP1 inhibited human breast                                               exons 7 8, inhibited VEGF165 binding PAE&#226;&#8364;&#8216;NRP1 cells <br /> carcinoma cell migration mechanism implying sequestering                                             PAE cells expressing VEGF receptor tyrosine kinases <br /> endogenous VEGF165.56 Taken together, data suggest NRP                                            (VEGFR&#226;&#8364;&#8216;1 VEGFR&#226;&#8364;&#8216;2).59 The bicyclic peptide, however, did <br /> soluble isoforms act VEGF165 antagonists sequester                                             inhibit cross&#226;&#8364;&#8216;linking VEGF165 VEGFR&#226;&#8364;&#8216;2 ECs coexpressing <br /> VEGF165 prevent tumorigenic angiogenic effects                                                   VEGFR&#226;&#8364;&#8216;2 NRP1, result inhibited VEGF165 signaling, <br /> &#194;&#173;mediated full&#226;&#8364;&#8216;length NRP.                                                                            e.g., VEGFR&#226;&#8364;&#8216;2, PLC&#226;&#8364;&#8216;g ERK phosphorylation.59 The importance <br />      VEGF165 exons 7/8 binds solely NRP B domain                                              VEGF exon 8 NRP binding substantiated a <br />  (Geretti E Klagsbrun M, unpublished).8,9,57 Thus, NRP B                                               study showing Tuftsin (TKPR), analogue VEGF exon 8 <br />  domain peptide potential competitive inhibitor VEGF&#226;&#8364;&#8216;NRP                                             (CDKPRR), inhibited VEGF165 binding NRP1.60 An analogous <br />  &#194;&#173;interactions. An advantage NRP B domain peptide                                            synthetic peptide, TKPPR, higher affinity antagonist. <br />   targets VEGF165 only, SEMAs, require                                        TKPPR inhibited VEGF165&#226;&#8364;&#8216;induced VEGFR&#226;&#8364;&#8216;2 activation without <br />   A B domains optimal interaction receptor (Geretti&#194;&#160;E                                       directly inhibiting VEGF165 binding VEGFR&#226;&#8364;&#8216;2. Another peptide, <br />   Klagsbrun M, unpublished).9,10 This selectivity                                               ATWLLPR (A7R), inhibited VEGF165 binding NRP1 not <br />   &#194;&#173;important vivo anti&#226;&#8364;&#8216;angiogenesis applications                                       VEGFR&#226;&#8364;&#8216;2. A7R inhibited EC proliferation, tube formation and <br />  <br />  <br /> www.landesbioscience.com	                                                            Cell Adhesion &amp; Migration	                                                                                                 59 <br />                                                                                     Neuropilins Angiogenesis <br />  <br />  <br /> growth MDA&#226;&#8364;&#8216;MB231 mouse xenografts.61 Taken                                          	 6.	 He Z, Tessier&#226;&#8364;&#8216;Lavigne M. Neuropilin receptor axonal chemorepellent <br />                                                                                                           Semaphorin III. Cell 1997; 90:739&#226;&#8364;&#8216;51. <br /> appears class VEGF165 inhibitors developed                                 	 7.	 Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin&#226;&#8364;&#8216;1 expressed by <br /> consists rationally designed peptides purpose blocking                                      endothelial tumor cells isoform&#226;&#8364;&#8216;specific receptor vascular endothelial growth <br /> VEGF&#226;&#8364;&#8216;NRP interactions.                                                                                    factor. Cell 1998; 92:735&#226;&#8364;&#8216;45. <br />                                                                                                    	 8.	 Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M. <br />                                                                                                           Neuropilin&#226;&#8364;&#8216;1 binds vascular endothelial growth factor 165, placenta growth factor&#226;&#8364;&#8216;2, and <br /> Future Directions NRP Research                                                                        heparin b1b2 domain. J Biol Chem 2002; 277:24818&#226;&#8364;&#8216;25. <br />                                                                                                    	 9.	 Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, Ginty DD, <br />         There solid evidence NRPs mediate tumor progression,                                      Kolodkin AL. Characterization neuropilin&#226;&#8364;&#8216;1 structural features confer bind- <br />                                                                                                           ing semaphorin 3A vascular endothelial growth factor 165. J Biol Chem 2002; <br /> either stimulators VEGF&#226;&#8364;&#8216;mediated pathways inhibitors                                          277:18069&#226;&#8364;&#8216;76. <br /> in SEMA&#226;&#8364;&#8216;mediated pathways. Several areas research prove                                   	 10.	 Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM. Neuropilin&#226;&#8364;&#8216;1 extracel- <br /> to beneficial. One develop NRP &#194;&#173; antagonists                                          lular domains mediate semaphorin D/III&#226;&#8364;&#8216;induced growth cone collapse. Neuron 1998; <br /> in rational manner. For example, anti&#226;&#8364;&#8216;NRP1 antibody                                                 21:1093&#226;&#8364;&#8216;100. <br />                                                                                                    	 11.	 Wang L, Mukhopadhyay D, Xu X. C terminus RGS&#226;&#8364;&#8216;GAIP&#226;&#8364;&#8216;interacting protein conveys <br /> proven effective inhibiting tumor growth combination                                          neuropilin&#226;&#8364;&#8216;1&#226;&#8364;&#8216;mediated signaling angiogenesis. Faseb J 2006; 20:1513&#226;&#8364;&#8216;5. <br /> with anti&#226;&#8364;&#8216;VEGF antibody. An anti&#226;&#8364;&#8216;NRP2 antibody prove                                         	 12.	 Cai H, Reed RR. Cloning characterization neuropilin&#226;&#8364;&#8216;1&#226;&#8364;&#8216;interacting protein: A <br /> to useful curbing tumor progression combination                                             PSD&#226;&#8364;&#8216;95/Dlg/ZO&#226;&#8364;&#8216;1 domain&#226;&#8364;&#8216;containing protein interacts cytoplasmic domain <br />                                                                                                           neuropilin&#226;&#8364;&#8216;1. J Neurosci 1999; 19:6519&#226;&#8364;&#8216;27. <br /> anti&#226;&#8364;&#8216;NRP1 antibody. An anti&#226;&#8364;&#8216;NRP2 antibody useful in <br />                                                                                                    	 13.	 Gao Y, Li M, Chen W, Simons M. Synectin, syndecan&#226;&#8364;&#8216;4 cytoplasmic domain binding PDZ <br /> inhibiting &#194;&#173;lymphangiogenesis tumors lymphatic EC express                                        protein, inhibits cell migration. J Cell Physiol 2000; 184:373&#226;&#8364;&#8216;9. <br /> solely NRP2.                                                                                       	 14.	 Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Elfenbein A, <br />                                                                                                           Ruiz Almodovar C, Dedkov E, Tomanek R, Li W, Westmore M, Singh JP, Horowitz A, <br />         Besides antibody approach, strategy                                     Mulligan&#226;&#8364;&#8216;Kehoe MJ, Moodie KL, Zhuang ZW, Carmeliet P, Simons M. Selective regulation <br /> &#194;&#173;developed holds promise target VEGF exon 7 &#194;&#173;interactions                                       arterial branching morphogenesis synectin. Dev Cell 2006; 10:783&#226;&#8364;&#8216;95. <br />  NRP B domain. NRP soluble fragments VEGF exons                                       	 15.	 Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G. Differential expression neuro- <br />                                                                                                           pilin&#226;&#8364;&#8216;1 neuropilin&#226;&#8364;&#8216;2 arteries veins. Mech Dev 2001; 109:115&#226;&#8364;&#8216;9. <br />  7/8 mimetics described studies                               	 16.	 Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, Eichmann A. <br />  expanded. The availability B domain crystal structures,                                        Abnormal lymphatic vessel development neuropilin 2 mutant mice. Development 2002; <br />  example, b1 domain NRP162 B domain NRP1,                                               129:4797&#226;&#8364;&#8216;806. <br />                                                                                                    	 17.	 Eichmann A, Yuan L, Moyon D, Lenoble F, Pardanaud L, Breant C. Vascular develop- <br />  cocrystallized Tuftsin,63 offer valuable starting points rational                               ment: <span id='am-2' about='protege:FROM' typeof='owl:Thing'>From</span> precursor cells branched arterial venous networks. Int J Dev Biol 2005; <br />  structure-based inhibitor design. For example, &#194;&#173; mutations B                                      49:259&#226;&#8364;&#8216;67. <br />  domain bind VEGF tightly efficient                                    	 18.	 Yaniv K, Isogai S, Castranova D, Dye L, Hitomi J, Weinstein BM. Live imaging lym- <br />                                                                                                           phatic development zebrafish. Nat Med 2006; 12:711&#226;&#8364;&#8216;6. <br />  sequestering VEGF (Geretti E Klagsbrun M, unpublished). In                                    	 19.	 Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression mem- <br />  strategies, important affect adversely                                   brane protein, neuropilin, chimeric mice causes anomalies cardiovascular system, <br />  SEMA binding NRPs SEMAs inhibitors tumor                                            nervous limbs. Development 1995; 121:4309&#226;&#8364;&#8216;18. <br />                                                                                                    	 20.	 Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H. A requirement <br />  progression.                                                                                             neuropilin&#226;&#8364;&#8216;1 embryonic vessel formation. Development 1999; 126:4895&#226;&#8364;&#8216;902. <br />         Another important aspect NRP relationship tumors                               	 21.	 Chen H, Bagri A, Zupicich JA, Zou Y, Stoeckli E, Pleasure SJ, Lowenstein DH, Skarnes <br />  expand analysis NRPs expression VEGF                                             WC, Chedotal A, Tessier&#226;&#8364;&#8216;Lavigne M. Neuropilin&#226;&#8364;&#8216;2 regulates development selec- <br />                                                                                                           tive cranial sensory nerves hippocampal mossy fiber projections. Neuron 2000; <br />  SEMAs levels patients. So far, seven                                  25:43&#226;&#8364;&#8216;56. <br />  tumor types increase NRP1, NRP2 NRP levels.                                    	 22.	 Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, Niwa H, Miyazaki <br />                                                                                                           Ji J, Hirota S, Kitamura Y, Kitsukawa T, Fujisawa H, Klagsbrun M, Hori M. Targeting of <br />  A larger sampling patient data critical &#194;&#173; ascertaining                                    mouse neuropilin&#226;&#8364;&#8216;1 neuropilin&#226;&#8364;&#8216;2 genes severely impairs developmental yolk sac and <br />  &#194;&#173;reliability. Most work based immunohistological                                           embryonic angiogenesis. Proc Natl Acad Sci USA 2002; 99:3657&#226;&#8364;&#8216;62. <br />   &#194;&#173;analysis tumor sections beneficial develop                                	 23.	 Lee P, Goishi K, Davidson AJ, Mannix R, Zon L, Klagsbrun M. Neuropilin&#226;&#8364;&#8216;1 required <br />                                                                                                           vascular development mediator VEGF&#226;&#8364;&#8216;dependent angiogenesis zebrafish. <br />    quantitative analytical methods (e.g., ELISA) purpose.                                   Proc Natl Acad Sci USA 2002; 99:10470&#226;&#8364;&#8216;5. <br />    An interesting possibility VEGF/SEMA ratios                                	 24.	 Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin a <br />    &#194;&#173;diagnostic. Finding ways upregulating endogenous SEMAs (3A,                                        semaphorin III receptor. Cell 1997; 90:753&#226;&#8364;&#8216;62. <br />                                                                                                    	 25.	 Nakamura F, Kalb RG, Strittmatter SM. Molecular basis semaphorin&#226;&#8364;&#8216;mediated axon <br />     3B 3F) counteract VEGF activity.                                                            guidance. J Neurobiol 2000; 44:219&#226;&#8364;&#8216;29. <br />         In summary, NRPs mediate stimulation (VEGF)                                 	 26.	 Tamagnone L, Comoglio PM. Signalling semaphorin receptors: Cell guidance and <br />     inhibition (SEMA) tumor angiogenesis progression.                                       beyond. Trends Cell Biol 2000; 10:377&#226;&#8364;&#8216;83. <br />                                                                                                    	 27.	 Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, <br />     Inhibiting VEGF&#226;&#8364;&#8216;NRP interactions promoting SEMA&#226;&#8364;&#8216;NRP                                             Primo L, Tamagnone L, Logan M, Tessier&#226;&#8364;&#8216;Lavigne M, Taniguchi M, Puschel AW, Bussolino <br />     interactions rational approaches regulating tumor                                         F. Class 3 semaphorins control vascular morphogenesis inhibiting integrin function. <br />     &#194;&#173;angiogenesis progression.                                                                        Nature 2003; 424:391&#226;&#8364;&#8216;7. <br />                                                                                                    	 28.	 Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin&#226;&#8364;&#8216;1 mediates <br />     References                                                                                            collapsin&#226;&#8364;&#8216;1/semaphorin III inhibition endothelial cell motility: Functional competition <br /> 	 1.	 Ferrara N, Kerbel RS. Angiogenesis therapeutic target. Nature 2005; 438:967&#226;&#8364;&#8216;74.                collapsin&#226;&#8364;&#8216;1 vascular endothelial growth factor&#226;&#8364;&#8216;165. J Cell Biol 1999; 146:233&#226;&#8364;&#8216;42. <br /> 	 2.	 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY.                     	 29.	 Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, Klagsbrun M. <br />       Ranibizumab neovascular age&#226;&#8364;&#8216;related macular degeneration. N Engl J Med 2006;                    Semaphorin 3F, chemorepulsant endothelial cells, induces poorly vascularized, encap- <br />                                                                                                           sulated, nonmetastatic tumor phenotype. J Clin Invest 2004; 114:1260&#226;&#8364;&#8216;71. <br />       355:1419&#226;&#8364;&#8216;31. <br />                                                                                                    	 30.	 Tse C, Xiang RH, Bracht T, Naylor SL. Human Semaphorin 3B (SEMA3B) located at <br /> 	 3.	 Hurwitz H, Saini S. Bevacizumab treatment metastatic colorectal cancer: Safety <br />                                                                                                           chromosome 3p21.3 suppresses tumor formation adenocarcinoma cell line. Cancer <br />       profile management adverse events. Semin Oncol 2006; 33:S26&#226;&#8364;&#8216;34. <br />                                                                                                           Res 2002; 62:542&#226;&#8364;&#8216;6. <br /> 	 4.	 Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee         	 31.	 Futamura M, Kamino H, Miyamoto Y, Kitamura N, Nakamura Y, Ohnishi S, Masuda Y, <br />       SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri               Arakawa H. Possible role semaphorin 3F, candidate tumor suppressor gene 3p21.3, <br />       A, Tessier&#226;&#8364;&#8216;Lavigne M, Watts RJ. Blocking neuropilin&#226;&#8364;&#8216;1 function additive effect          p53&#226;&#8364;&#8216;regulated tumor angiogenesis suppression. Cancer Res 2007; 67:1451&#226;&#8364;&#8216;60. <br />       anti&#226;&#8364;&#8216;VEGF inhibit tumor growth. Cancer Cell 2007; 11:53&#226;&#8364;&#8216;67.                               	 32.	 Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, Albanesi JP, Lee CC, Lerman MI, <br /> 	 5.	 Takagi S, Tsuji T, Amagai T, Takamatsu T, Fujisawa H. Specific cell surface labels           Minna JD. Human semaphorins A(V) IV reside 3p21.3 small cell lung cancer <br />       visual centers Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol           deletion region demonstrate distinct expression patterns. Proc Natl Acad Sci USA 1996; <br />       1987; 122:90&#226;&#8364;&#8216;100.                                                                                   93:4120&#226;&#8364;&#8216;5. <br />  <br />  <br /> 60	                                                                           Cell Adhesion &amp; Migration	                                                                2007; Vol. 1 Issue 2 <br />                                                                                        Neuropilins Angiogenesis <br />  <br />  <br /> 	 33.	 Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J, Henderson CE, Jessell TM,                	 55.	 Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klagsbrun M. <br />        Kolodkin AL, Ginty DD. Semaphorin 3E plexin&#226;&#8364;&#8216;D1 control vascular <span id='am-239' about='xsp:pattern' typeof='owl:Thing'>pattern</span> indepen-                   Identification natural soluble neuropilin&#226;&#8364;&#8216;1 binds vascular endothelial growth factor: <br />        dently neuropilins. Science 2005; 307:265&#226;&#8364;&#8216;8.                                                        In vivo expression antitumor activity. Proc Natl Acad Sci USA 2000; 97:2573&#226;&#8364;&#8216;8. <br /> 	 34.	 Adams RH, Lohrum M, Klostermann A, Betz H, Puschel AW. The chemorepulsive activity              	 56.	 Cackowski FC, Xu L, Hu B, Cheng SY. Identification novel alternatively spliced <br />        secreted semaphorins regulated furin&#226;&#8364;&#8216;dependent proteolytic processing. Embo J                 Neuropilin&#226;&#8364;&#8216;1 isoforms. Genomics 2004; 84:82&#226;&#8364;&#8216;94. <br />        1997; 16:6077&#226;&#8364;&#8216;86.                                                                               	 57.	 Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L, <br /> 	 35.	 Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, Tamagnone L,                         Alitalo K. Functional interaction VEGF&#226;&#8364;&#8216;C VEGF&#226;&#8364;&#8216;D neuropilin receptors. Faseb <br />        Guldberg P, Lukanidin E. Proteolytic processing converts repelling signal Sema3E              J 2006; 20:1462&#226;&#8364;&#8216;72. <br />        inducer invasive growth lung metastasis. Cancer Res 2005; 65:6167&#226;&#8364;&#8216;77.                 	 58.	 Soker S, Gollamudi&#226;&#8364;&#8216;Payne S, Fidder H, Charmahelli H, Klagsbrun M. Inhibition of <br /> 	 36.	 Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, Katsuyama Y, Konishi I. Expression                     vascular endothelial growth factor (VEGF)&#226;&#8364;&#8216;induced endothelial cell proliferation a <br />        semaphorins, vascular endothelial growth factor, common receptor neuropil-                peptide corresponding exon 7&#226;&#8364;&#8216;encoded domain VEGF165. J Biol Chem 1997; <br />        ins alleic loss semaphorin locus epithelial ovarian neoplasms: Increased ratio            272:31582&#226;&#8364;&#8216;8. <br />        vascular endothelial growth factor semaphorin poor prognostic factor ovarian         	 59.	 Jia H, Bagherzadeh A, Hartzoulakis B, Jarvis A, Lohr M, Shaikh S, Aqil R, Cheng L, Tickner <br />        carcinomas. Hum Pathol 2006; 37:1414&#226;&#8364;&#8216;25.                                                               M, Esposito D, Harris R, Driscoll PC, Selwood DL, Zachary IC. Characterization a <br /> 	 37.	 Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin&#226;&#8364;&#8216;1 expression tumor cells                    bicyclic peptide neuropilin&#226;&#8364;&#8216;1 (NP&#226;&#8364;&#8216;1) antagonist (EG3287) reveals importance vascular <br />        promotes tumor angiogenesis progression. Faseb J 2000; 14:2532&#226;&#8364;&#8216;9.                                  endothelial growth factor exon 8 NP&#226;&#8364;&#8216;1 binding role NP&#226;&#8364;&#8216;1 KDR signaling. J <br /> 	 38.	 Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O, Reinmuth N, Bielenberg D, Bucana                     Biol Chem 2006; 281:13493&#226;&#8364;&#8216;502. <br />        CD, Klagsbrun M, Ellis LM. Neuropilin&#226;&#8364;&#8216;1 human colon cancer: Expression, regulation,          	 60.	 von Wronski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappan P, Ramalingam <br />        role induction angiogenesis. Am J Pathol 2004; 164:2139&#226;&#8364;&#8216;51.                                  K, Arunachalam T, Eaton S, Linder KE, Yan F, Pochon S, Tweedle MF, Nunn AD. Tuftsin <br /> 	 39.	 Hu B, Guo P, Bar&#226;&#8364;&#8216;Joseph I, Imanishi Y, Jarzynka MJ, Bogler O, Mikkelsen T, Hirose T,                   binds neuropilin&#226;&#8364;&#8216;1 sequence similar encoded exon 8 vascular endo- <br />        Nishikawa R, Cheng SY. Neuropilin&#226;&#8364;&#8216;1 promotes human glioma progression poten-                   thelial growth factor. J Biol Chem 2006; 281:5702&#226;&#8364;&#8216;10. <br />        tiating activity HGF/SF autocrine pathway. Oncogene 2007.                            	 61.	 Starzec A, Vassy R, Martin A, Lecouvey M, Di Be <br /> </body></html>